drugset / Trial / NCT03283267

A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

NCT03283267

Phase 1 Completed 22 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single center, inpatient, open label pharmacodynamic study to determine the effect of 5 g and 10 g doses of Sodium Zirconium Cyclosilicate (ZS) administered once daily (qd) for 4 days on potassium and sodium excretion in healthy Chinese subjects on a standardized, low sodium and high potassium diet.

Timeline

Start
2017-10-24
Primary completion
2017-11-23
Completion
2017-11-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Zirconium Cyclosilicate Other / unclassified 5 g Oral
Subject Sodium Zirconium Cyclosilicate Other / unclassified 10 g Oral

Indications

No indication recorded.